Studies of the pathophysiological mechanisms in frontotemporal dementia by proteome analysis of CSF proteins

Molecular Brain Research

Volumn 109, Issue 1-2, 2002, Pages 128-133

  Davidsson, Pia ^a   Sjögren, Magnus ^a   Andreasen, Niels ^b   Lindbjer, Maria ^a   Nilsson, Carol L ^a   Westman Brinkmalm, Ann ^a   Blennow, Kaj ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b Pitea River Valley Hospital   (Sweden)

Author keywords

Cerebrospinal fluid; Frontotemporal dementia; Granin like neuroendocrine precursor; Haptoglobin; Pigment epithelium derived factor; Proteomics; Retinol binding protein

Indexed keywords

ALBUMIN; APOLIPOPROTEIN E; BRAIN PROTEIN; GRANIN LIKE NEUROENDOCRINE PRECURSOR PROTEIN; HAPTOGLOBIN; PIGMENT EPITHELIUM DERIVED FACTOR; PROTEOME; RETINOL BINDING PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FRONTOTEMPORAL DEMENTIA; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CEREBROSPINAL FLUID LEVEL;

AGED; CEREBROSPINAL FLUID; DEMENTIA; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HUMANS; MIDDLE AGED; PROTEOME; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 0037203346     PISSN: 0169328X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-328X(02)00549-1     Document Type: Article

References (37)

1. Abbruzzese M., Ferri S., Scarone S. The selective breakdown of frontal functions in patients with obsessive-compulsive disorder and in patients with schizophrenia: a double dissociation experimental finding. Neuropsychologia. 35:1997;907-912.
2. Andreasen N., Minthon L., Clarberg A., Davidsson P., Gottfries J., Vanmechelen E., Vanderstichele H., Winblad B., Blennow K. Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample. Neurology. 22:1999;1488-1494.
3. Arai H., Morikawa Y., Higuchi M., Matsui T., Clark C.M., Miura M., Machida N., Lee V.M., Trojanowski J.Q., Sasaki H. Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology. Biochem. Biophys. Res. Commun. 236:1997;262-264.
4. Bilak M.M., Corse A.M., Bilak S.R., Lehar M., Tombran-Tink J., Kuncl R.W. Pigment epithelium-derived factor (PEDF) protects motor neurons from chronic glutamate-mediated neurodegeneration. J. Neuropathol. Exp. Neurol. 58:1999;719-728.
5. Blennow K., Wallin A., Gottfries C.G. Presence of parieto-temporal symptomatology distinguishing early and late onset Alzheimer's disease. Int. J. Geriatr. Psychiatry. 6:1991;147-154.
6. Blennow K., Wallin A., Ågren H., Spenger C., Siegfried J., Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol. Chem. Neuropathol. 26:1995;231-245.
7. Breitner J.C. The role of anti-inflammatory drugs in the prevention and treatment of Alzheimer's disease. Annu. Rev. Med. 47:1996;401-411.
8. Brun A. Frontal lobe degeneration of non-Alzheimer type I, Neuropathology. Arch. Gerontol. Geriatr. 6:1987;93-208.
9. Brun A., Englund B., Gustafsson L., Passant U., Mann D.M.A., Neary D., Snowden J.S. Clinical and neuropathological criteria for frontotemporal dementia. J. Neurol. Neurosurg. Psychiatry. 57:1994;416-418.
10. Cavedini P., Ferri S., Scarone S., Bellodi L. Frontal lobe dysfunction in obsessive-compulsive disorder and major depression: a clinical-neuropsychological study. Psychiatry Res. 78:1998;21-28.
11. Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Small G.W., Roses A.D., Haines J.L., Pericak-Vance M.A. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 261:1993;921-923.
12. Davidsson P., Westman-Brinkmalm A., Nilsson C.L., Lindbjer M., Paulson L., Andreasen N., Sjögren M., Blennow K. Proteome analysis of cerebrospinal fluid proteins in Alzheimer patients. Neuroreport. 13:(5):2002;611-615.
13. Delacourte A., Robitaille Y., Sergeant N., Buee L., Hof P.R., Wattez A., Laroche-Cholette A., Mathieu J., Chagnon P., Gauvreau D. Specific pathological Tau protein variants characterize Pick's disease. Neuropathol. Exp. Neurol. 55:(2):1996;159-168.
14. Feng Y., Reznik S.E., Fricker L.D. Distribution of proSAAS-derived peptides in rat neuroendocrine tissues. Neuroscience. 105:(2):2001;469-478.
15. Fricker L.D., McKinzie A.A., Sun J., Curran E., Qian Y., Yan L., Patterson S.D., Courchesne P.L., Richards B., Levin N., Mzhavia N., Devi L.A., Douglass J. Identification and characterization of proSAAS, a granin-like neuroendocrine peptide precursor that inhibits prohormone processing. J. Neurosci. 20:(2):2000;639-648.
16. Froelich Fabre S., Forsell C., Viitanen M., Sjögren M., Wallin A., Blennow K., Blomberg M., Andersen C., Wahlund L.O., Lannfelt L. Clinic-based cases with frontotemporal dementia show increased cerebrospinal fluid tau and high apolipoprotein E varepsilon 4 frequency, but no tau gene mutations. Exp. Neurol. 168:2001;413-418.
17. Galasko D., Chang L., Motter R., Clark C.M., Kaye J., Knopman D., Thomas R., Kholodenko D., Schenk D., Lieberburg I., Miller B., Green R., Basherad R., Kertiles L., Boss M.A., Seubert P. High cerebrospinal fluid tau and low amyloid beta-42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch. Neurol. 55:(7):1998;937-945.
18. Geschwind D., Karrim J., Nelson S.F., Miller B. The apolipoprotein E epsilon4 allele is not a significant risk factor for frontotemporal dementia. Ann. Neurol. 44:1998;134-138.
19. Green A.J., Harvey R.J., Thompson E.J., Rossor M.N. Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease. Neurosci. Lett. 259:(2):1999;133-135.
20. Gustafson L. Clinical picture of frontal lobe degeneration of non-Alzheimer type. Dementia. 4:1993;143-148.
21. Hesse C., Bogdanovic N., Davidsson P., Blennow K. A quantitative and immunohistochemical study on apolipoprotein E in brain tissue in Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 10:(6):1999;452-459.
22. Hesse C., Larsson H., Fredman P., Minthon L., Andreasen N., Davidsson P., Blennow K. Measurement of apolipoprotein E (apoE) in cerebrospinal fluid. Neurochem. Res. 25:(4):2000;511-517.
23. Johnson G., Brane D., Block W., van Kammen D.P., Gurklis J., Peters J.L., Wyatt R.J., Kirch D.G., Ghanbari H.A., Merril C.R. Cerebrospinal fluid proteins variations in common to Alzheimer's disease and schizophrenia. Appl. Theor. Electrophoresis. 3:1992;47-53.
24. Maury C.P., Teppo A.M. Immunodetection of protein composition in cerebral amyloid extracts in Alzheimer's disease: enrichment of retinol-binding protein. J. Neurol. Sci. 80:(2-3):1987;221-228.
25. Mecocci P., Cherubini A., Bregnocchi M., Chionne F., Cecchetti R., Lowenthal D.T., Senin U. Tau protein in cerebrospinal fluid: a new diagnostic and prognostic marker in Alzheimer disease? Alzheimer Dis. Assoc. Disord. 12:1998;211-214.
26. Minthon L., Hesse C., Sjögren M., Englund E., Gustafson L., Blennow K. The apolipoprotein E epsilon4 allele frequency is normal in fronto-temporal dementia, but correlates with age at onset of disease. Neurosci. Lett. 226:(1):1997;65-67.
27. Pasinetti G.M. Inflammatory mechanisms in neurodegeneration and Alzheimer's disease: the role of the complement system. Neurobiol. Aging. 17:1996;707-716.
28. Perez-Mediavilla L.A., Chew C., Campochiaro P.A., Nickells R.W., Notario V., Zack D.J., Becerra S.P. Sequence and expression analysis of bovine pigment epithelium-derived factor. Biochim. Biophys. Acta. 1398:(2):1998;203-214.
29. Pickering-Brown S.M., Owen F., Isaacs A., Snowden J., Varma A., Neary D., Furlong R., Daniel S.E., Cairns N.J., Mann D.M. Apolipoprotein E epsilon4 allele has no effect on age at onset or duration of disease in cases of frontotemporal dementia with pick- or microvacuolar-type histology. Exp. Neurol. 63:2000;452-456.
30. Qian Y., Devi L.A., Mzhavia N., Munzer S., Seidah N.G., Fricker L.D. The C-terminal region of proSAAS is a potent inhibitor of prohormone convertase 1. J. Biol. Chem. 275:(31):2000;23596-23601.
31. Saunders A.M., Strittmatter W.J., Schmechel D., George-Hyslop P.H., Pericak-Vance M.A., Joo S.H., Rosi B.L., Gusella J.F., Crapper-MacLachlan D.R., Alberts M.J., et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology. 43:(8):1993;1467-1472.
32. Shevchenko A., Wilm M., Mann M. Peptide sequencing by mass spectrometry for homology searches and cloning of genes. J. Protein Chem. 16:(5):1997;481-490.
33. Sjögren M., Edman Å., Wallin A. Symptomatological characteristics distinguish between frontotemporal dementia and vascular dementia with a dominant frontal lobe syndrome. Int. J. Geriatr. Psychiatry. 12:1997;656-661.
34. Sjögren M., Rosengren L., Minthon L., Davidsson P., Blennow K., Wallin A. Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD. Neurology. 54:(10):2000;960-964.
35. Strittmatter W.J., Roses A.D. Apolipoprotein E and Alzheimer's disease. Annu. Rev. Neurosci. 19:1996;53-77.
36. Sugita Y., Becerra S.P., Chader G.J., Schwartz J.P. Pigment epithelium-derived factor (PEDF) has direct effects on the metabolism and proliferation of microglia and indirect effects on astrocytes. J. Neurosci. Res. 49:(6):1997;701-708.
37. Westman A., Nilsson C.L., Ekman R. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry analysis of proteins in human cerebrospinal fluid. Rapid Commun. Mass Spectrom. 12:(16):1998;1092-1098.